Halozyme sues Mer­ck, al­leg­ing in­jectable Keytru­da will in­fringe its patents

San Diego biotech Halozyme is su­ing Mer­ck over an in­jectable ver­sion of its block­buster can­cer drug, al­leg­ing that the new for­mu­la­tion will in­fringe on Halozyme’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER